Pipeline (Phase 3)

Pemvidutide (pemvidutide)

Altimmune's pemvidutide (also branded Nexaph). Dual GLP-1/glucagon agonist.

Get Prescribed Online — $179/mo → 60-Second Quiz

Avg weight loss

~15.6%

Cost

Not

Dosing

Once weekly

FDA Status

Pipeline

Pemvidutide is Altimmune's dual GLP-1 / glucagon agonist (also referred to as Nexaph in some materials). It is in Phase 3 trials for obesity and MASH/NASH.

Overview

Pemvidutide combines GLP-1 receptor agonism with glucagon receptor agonism in a once-weekly injection. Phase 2 trials showed 15.6% weight loss and notable reductions in liver fat — making it especially promising for MASH/NASH.

How Pemvidutide Works

GLP-1 activity for appetite suppression; glucagon activity for energy expenditure and direct liver-fat reduction.

Dosing & Schedule

Weekly subcutaneous injection. Phase 3 doses still being optimized.

Effectiveness — Trial Data

Phase 2 (48 weeks): 15.6% weight loss.

Side Effects

Standard GLP-1 GI profile.

Cost — How Much Pemvidutide Costs in 2026

Not yet on market.

Who Is Pemvidutide For?

Investigational. Likely future indications: obesity, MASH/NASH.

Pemvidutide Alternatives

Available now: tirzepatide, semaglutide.

Frequently Asked Questions

Is pemvidutide the same as Nexaph?

Yes. Some materials refer to Altimmune's dual GLP-1/glucagon agonist as Nexaph; the active ingredient is pemvidutide.